New treatment approach for liver cancer using a special dye
Radioiodinated Indocyanine Green: A Novel Liver Cancer Therapeutic Modality
This study is exploring a new way to treat liver cancer by using a special dye that can deliver targeted radiation directly to the tumors, and it's designed for people who are facing liver cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | National Cancer Institute NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-10497368 on NIH RePORTER |
What this research studies
This research focuses on creating a new treatment for liver cancer by developing radioiodinated versions of indocyanine green (ICG), a dye that is already approved for medical use. The researchers aim to attach a radioactive isotope to ICG, which will allow it to target liver cancer cells specifically and deliver radiation directly to the tumors. The project includes testing these new compounds in laboratory models and studying how they behave in living organisms with liver tumors. This innovative approach combines expertise in dye synthesis and cancer treatment to potentially improve outcomes for patients with liver cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with liver cancer, particularly those with hepatocellular carcinoma or hepatoblastoma.
Not a fit: Patients with liver cancer types that do not express the solute carrier transporter targeted by this treatment may not benefit.
Why it matters
Potential benefit: If successful, this research could provide a targeted and effective treatment option for patients with liver cancer.
How similar studies have performed: Previous research has shown promising results using similar targeted approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Bethesda, United States
- National Cancer Institute — Bethesda, United States (Active)
Researchers
- Principal investigator: Marker, Sierra C — National Cancer Institute
- Study coordinator: Marker, Sierra C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.